Richard G. Margolese
Montreal, QC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 29, 2023
Margin Status and Local Recurrence in Phyllodes Tumours of the Breast: A Canadian Series.
Journal: Annals of surgical oncology
Published: July 25, 2022
Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer.
Journal: Breast cancer research and treatment
Published: August 13, 2021
Population-based analysis of non-operative management and treatment patterns in older women with estrogen receptor-positive breast cancer.
Journal: Breast cancer research and treatment
Published: May 17, 2021
Oncologic Safety of Sentinel Lymph Node Biopsy Alone After Neoadjuvant Chemotherapy for Breast Cancer.
Journal: Annals of surgical oncology
Published: July 02, 2020
Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30.
Journal: Journal of the National Cancer Institute
Published: January 20, 2017
The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40.
Journal: Annals of surgical oncology
Published: September 01, 2016
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Journal: Lancet (London, England)
Published: December 22, 2015
Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Journal: Lancet (London, England)
Published: December 22, 2015
Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29.
Journal: Breast cancer research and treatment
Published: August 10, 2015
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.
Journal: The Lancet. Oncology
Published: April 07, 2015
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Journal: The Lancet. Oncology
Published: October 08, 2013
Last Updated: 09/26/2026